Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00096
Abstract: Aberrant FGF19/FGFR4 signaling has been shown to be an oncogenic driver of growth and survival in human hepatocellular carcinoma (HCC) with several pan-FGFR inhibitors and FGFR4-selective inhibitors currently being evaluated in the clinic. However, FGFR4…
read more here.
Keywords:
fgfr4;
inhibitors wild;
type gatekeeper;
gatekeeper ... See more keywords